IFNβ Protects Neurons from Damage in a Murine Model of HIV-1 Associated Brain Injury

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Thaney, Victoria E ^a   O'Neill, Alan M ^a   Hoefer, Melanie M ^a   Maung, Ricky ^a   Sanchez, Ana B ^a   Kaul, Marcus ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; BETA INTERFERON; CCL4 PROTEIN, MOUSE; GLYCOPROTEIN GP 120; IFNAR1 PROTEIN, MOUSE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEUROPROTECTIVE AGENT;

ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN INJURY; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; RAT; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; BRAIN INJURIES; CELLS, CULTURED; CHEMOKINE CCL4; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; INTERFERON-BETA; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 85018991462     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46514     Document Type: Article

References (83)

1. Antinori, A. et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69, 1789-1799, doi: 10.1212/01.WNL.0000287431.88658.8b (2007).
2. Kaul, M., Garden, G. A. & Lipton, S. A. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410, 988-994 (2001).
3. Saylor, D. et al. HIV-associated neurocognitive disorder-pathogenesis and prospects for treatment. Nat Rev Neurol 12, 234-248, doi: 10.1038/nrneurol.2016.27 (2016).
4. Ellis, R. J. et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 54, 416-424 (1997).
5. Budka, H. Multinucleated giant cells in brain: a hallmark of the acquired immune deficiency syndrome (AIDS). Acta Neuropathol (Berl) 69, 253-258 (1986).
6. Navia, B. A., Cho, E. S., Petito, C. K. & Price, R. W. The AIDS dementia complex: II. Neuropathology. Ann Neurol 19, 525-535, doi: 10.1002/ana.410190603 (1986).
7. Masliah, E. et al. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 32, 321-329 (1992).
8. Masliah, E., Ge, N., Achim, C. L., Hansen, L. A. & Wiley, C. A. Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 51, 585-593 (1992).
9. Ellis, R., Langford, D. & Masliah, E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat. Rev. Neurosci 8, 33-44 (2007).
10. Bell, J. E. An update on the neuropathology of HIV in the HAART era. Histopathology 45, 549-559 (2004).
11. Kaul, M., Zheng, J., Okamoto, S., Gendelman, H. E. & Lipton, S. A. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 12 Suppl 1, 878-892, doi: 10.1038/sj.cdd.4401623 (2005).
12. Lindl, K. A., Marks, D. R., Kolson, D. L. & Jordan-Sciutto, K. L. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol 5, 294-309, doi: 10.1007/s11481-010-9205-z (2010).
13. Toggas, S. M. et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367, 188-193 (1994).
14. Valentin, A., Trivedi, H., Lu, W., Kostrikis, L. G. & Pavlakis, G. N. CXCR4 mediates entry and productive infection of syncytiainducing (X4) HIV-1 strains in primary macrophages. Virology 269, 294-304 (2000).
15. Maung, R. et al. CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J Immunol 193, 1895-1910 (2014).
16. D'hooge, R., Franck, F., Mucke, L. & De Deyn, P. P. Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur J Neurosci 11, 4398-4402 (1999).
17. Gelman, B. B. et al. The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS. ONE 7, e46178 (2012).
18. Wang, R. G., Kaul, M. & Zhang, D. X. Interferon-stimulated gene 15 as a general marker for acute and chronic neuronal injuries. Sheng Li Xue. Bao 64, 577-583 (2012).
19. Poli, G., Biswas, P. & Fauci, A. S. Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Res 24, 221-233 (1994).
20. Xiang, J. et al. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 363, 2040-2046 (2004).
21. Doyle, T., Goujon, C. & Malim, M. H. HIV-1 and interferons: who's interfering with whom? Nat Rev Microbiol 13, 403-413, doi: 10.1038/nrmicro3449 (2015).
22. Borden, E. C. et al. Interferons at age 50: past, current and future impact on biomedicine. Nature Reviews Drug Discovery 6, 975-990, doi: 10.1038/nrd2422 (2007).
23. Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481-485 (2011).
24. Samuel, C. E. Antiviral actions of interferons. Clin Microbiol Rev 14, 778-809, table of contents, doi: 10.1128/CMR.14.4.778- 809.2001 (2001).
25. Sas, A. R., Bimonte-Nelson, H. A. & Tyor, W. R. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS 21, 2151-2159 (2007).
26. Sas, A. R., Bimonte-Nelson, H., Smothers, C. T., Woodward, J. & Tyor, W. R. Interferon-alpha causes neuronal dysfunction in encephalitis. J Neurosci 29, 3948-3955 (2009).
27. Kitai, R., Zhao, M. L., Zhang, N., Hua, L. L. & Lee, S. C. Role of MIP-1beta and RANTES in HIV-1 infection of microglia: inhibition of infection and induction by IFNbeta. J Neuroimmunol 110, 230-239 (2000).
28. Barber, S. A., Herbst, D. S., Bullock, B. T., Gama, L. & Clements, J. E. Innate immune responses and control of acute simian immunodeficiency virus replication in the central nervous system. J Neurovirol 10 Suppl 1, 15-20 (2004).
29. Cocchi, F. et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells. Science 270, 1811-1815 (1995).
30. Garzino-Demo, A., DeVico, A. L., Cocchi, F. & Gallo, R. C. Beta-chemokines and protection from HIV type 1 disease. AIDS Res Hum Retroviruses 14 Suppl 2, S177-184 (1998).
31. Kaul, M. & Lipton, S. A. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 96, 8212-8216 (1999).
32. Kaul, M., Ma, Q., Medders, K. E., Desai, M. K. & Lipton, S. A. HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection. Cell Death Differ 14, 296-305, doi: 10.1038/sj.cdd.4402006 (2007).
33. Lu, H. T. et al. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J Exp Med 182, 1517-1525 (1995).
34. Hua, L. L., Liu, J. S., Brosnan, C. F. & Lee, S. C. Selective inhibition of human glial inducible nitric oxide synthase by interferon-beta: implications for multiple sclerosis. Ann Neurol 43, 384-387, doi: 10.1002/ana.410430317 (1998).
35. Hua, L. L. & Lee, S. C. Distinct patterns of stimulus-inducible chemokine mRNA accumulation in human fetal astrocytes and microglia. Glia 30, 74-81 (2000).
36. Paul, S., Ricour, C., Sommereyns, C., Sorgeloos, F. & Michiels, T. Type I interferon response in the central nervous system. Biochimie 89, 770-778 (2007).
37. Markowitz, C. E. Interferon-beta: mechanism of action and dosing issues. Neurology 68, S8-11 (2007).
38. Abt, M. C. et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 37, 158-170, doi: 10.1016/j.immuni.2012.04.011 (2012).
39. Kawashima, T. et al. Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-beta. Immunity 38, 1187-1197, doi: 10.1016/j.immuni.2013.02.024 (2013).
40. Sui, Y. et al. Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis. Am. J Pathol 164, 1557-1566 (2004).
41. Cinque, P. et al. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 168, 154-163, doi: 10.1016/j.jneuroim.2005.07.002 (2005).
42. Muller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 264, 1918-1921 (1994).
43. Sheikh, F., Dickensheets, H., Gamero, A. M., Vogel, S. N. & Donnelly, R. P. An essential role for IFN-beta in the induction of IFNstimulated gene expression by LPS in macrophages. J Leukoc Biol 96, 591-600, doi: 10.1189/jlb.2A0414-191R (2014).
44. Sui, Y. et al. CXCL10-induced cell death in neurons: role of calcium dysregulation. Eur J Neurosci 23, 957-964 (2006).
45. Kang, Y. J. et al. Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders. Ann. Neurol 68, 342-352 (2010).
46. Ross, T. M. et al. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 151, 66-77 (2004).
47. Thorne, R. G., Hanson, L. R., Ross, T. M., Tung, D. & Frey, W. H. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 152, 785-797 (2008).
48. Yang, C. H. et al. Identification of CXCL11 as a STAT3-dependent gene induced by IFN. J Immunol 178, 986-992 (2007).
49. Tarassishin, L., Bauman, A., Suh, H. S. & Lee, S. C. Anti-viral and anti-inflammatory mechanisms of the innate immune transcription factor interferon regulatory factor 3: relevance to human CNS diseases. J Neuroimmune Pharmacol 8, 132-144, doi: 10.1007/s11481-012-9360-5 (2013).
50. Medders, K. E., Sejbuk, N. E., Maung, R., Desai, M. K. & Kaul, M. Activation of p38 MAPK is required in monocytic and neuronal cells for HIV glycoprotein 120-induced neurotoxicity. J Immunol 185, 4883-4895 (2010).
51. Sanchez, A. B. et al. Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage. Antimicrob Agents Chemother 60, 168-179, doi: 10.1128/AAC.01632-15 (2016).
52. Sanchez, A. B. et al. CXCL12-induced neurotoxicity critically depends on NMDA receptor-gated and L-type Ca2+ channels upstream of p38 MAPK. J Neuroinflammation 13, 252, doi: 10.1186/s12974-016-0724-2 (2016).
53. Giulian, D., Wendt, E., Vaca, K. & Noonan, C. A. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes. Proc Natl Acad Sci USA 90, 2769-2773 (1993).
54. Genis, P. et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 176, 1703-1718 (1992).
55. O'Donnell, L. A. et al. Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. J Neurosci 26, 981-990 (2006).
56. Sui, Z. et al. Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factorkappaB survival pathway in neurons. Eur J Neurosci 23, 2623-2634 (2006).
57. Eggert, D. et al. Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol 184, 746-756 (2010).
58. Gauldie, J., Richards, C., Harnish, D., Lansdorp, P. & Baumann, H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84, 7251-7255 (1987).
59. Heaton, R. K. et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75, 2087-2096 (2010).
60. Akhtar, L. N. et al. Suppressor of cytokine signaling 3 inhibits antiviral IFN-beta signaling to enhance HIV-1 replication in macrophages. J Immunol 185, 2393-2404 (2010).
61. Griffin, D. E. Immune responses to RNA-virus infections of the CNS. Nat Rev Immunol 3, 493-502 (2003).
62. McLaurin, J., Antel, J. P. & Yong, V. W. Immune and non-immune actions of interferon-beta-Ib on primary human neural cells. Mult. Scler 1, 10-19 (1995).
63. van Heteren, J. T. et al. Astrocytes produce interferon-alpha and CXCL10, but not IL-6 or CXCL8, in Aicardi-Goutieres syndrome. Glia 56, 568-578 (2008).
64. Crow, Y. J. et al. Cree encephalitis is allelic with Aicardi-Goutieres syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. J Med Genet 40, 183-187 (2003).
65. Akwa, Y. et al. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol 161, 5016-5026 (1998).
66. Dudaronek, J. M., Barber, S. A. & Clements, J. E. CUGBP1 is required for IFNbeta-mediated induction of dominant-negative CEBPbeta and suppression of SIV replication in macrophages. J Immunol 179, 7262-7269 (2007).
67. Honda, K., Takaoka, A. & Taniguchi, T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25, 349-360 (2006).
68. Alammar, L., Gama, L. & Clements, J. E. Simian immunodeficiency virus infection in the brain and lung leads to differential type I IFN signaling during acute infection. J Immunol 186, 4008-4018 (2011).
69. Zaritsky, L. A., Gama, L. & Clements, J. E. Canonical type I IFN signaling in simian immunodeficiency virus-infected macrophages is disrupted by astrocyte-secreted CCL2. J Immunol 188, 3876-3885 (2012).
70. Berg, R. K. et al. Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA. PLoS ONE 7, e29291 (2012).
71. Furr, S. R., Chauhan, V. S., Sterka, D. Jr., Grdzelishvili, V. & Marriott, I. Characterization of retinoic acid-inducible gene-I expression in primary murine glia following exposure to vesicular stomatitis virus. J Neurovirol, 1-11 (2008).
72. Nazmi, A., Dutta, K. & Basu, A. RIG-I mediates innate immune response in mouse neurons following Japanese encephalitis virus infection. PLoS One 6, e21761, doi: 10.1371/journal.pone.0021761 (2011).
73. Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat Rev Immunol 14, 36-49, doi: 10.1038/nri3581 (2014).
74. Thorne, R. G. & Frey, W. H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet 40, 907-946 (2001).
75. Thorne, R. G., Pronk, G. J., Padmanabhan, V. & Frey, W. H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496 (2004).
76. Hanson, L. R. & Frey, W. H. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol 2, 81-86, doi: 10.1007/s11481-006-9039-x (2007).
77. Lochhead, J. J., Wolak, D. J., Pizzo, M. E. & Thorne, R. G. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cerebr Blood F Met 35, 371-381, doi: 10.1038/jcbfm.2014.215 (2015).
78. Tarassishin, L., Suh, H. S. & Lee, S. C. Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway. J Neuroinflammation 8, 187, doi: 10.1186/1742-2094-8-187 (2011).
79. Hoefer, M. M. et al. Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system. Exp Neurol 263, 221-234 (2015).
80. Khorooshi, R. & Owens, T. Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system. J Immunol 185, 1258-1264, doi: 10.4049/jimmunol.0901753 (2010).
81. Shimizu, K., Asakura, M. & Fujii, S. Prolonged antitumor NK cell reactivity elicited by CXCL10-expressing dendritic cells licensed by CD40L+ CD4+ memory T cells. J Immunol 186, 5927-5937, doi: 10.4049/jimmunol.1003351 (2011).
82. Schneider, K. et al. Lymphotoxin-mediated crosstalk between B cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus. Cell Host. Microbe 3, 67-76 (2008).
83. Yoshida, H., Okabe, Y., Kawane, K., Fukuyama, H. & Nagata, S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat Immunol 6, 49-56, doi: 10.1038/ni1146 (2005).